MA43019A - Anticorps anti-humain cd19 à affinité élevée - Google Patents
Anticorps anti-humain cd19 à affinité élevéeInfo
- Publication number
- MA43019A MA43019A MA043019A MA43019A MA43019A MA 43019 A MA43019 A MA 43019A MA 043019 A MA043019 A MA 043019A MA 43019 A MA43019 A MA 43019A MA 43019 A MA43019 A MA 43019A
- Authority
- MA
- Morocco
- Prior art keywords
- high affinity
- human antibodies
- antibodies
- human
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188262 | 2015-10-02 | ||
| EP16167893 | 2016-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43019A true MA43019A (fr) | 2018-08-08 |
Family
ID=57042875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043019A MA43019A (fr) | 2015-10-02 | 2016-09-28 | Anticorps anti-humain cd19 à affinité élevée |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180230215A1 (fr) |
| EP (1) | EP3356405A1 (fr) |
| JP (1) | JP6918789B2 (fr) |
| KR (1) | KR102761077B1 (fr) |
| CN (1) | CN108137698B (fr) |
| AU (1) | AU2016330807B2 (fr) |
| CA (1) | CA3000045C (fr) |
| CL (1) | CL2018000829A1 (fr) |
| CO (1) | CO2018004532A2 (fr) |
| CR (1) | CR20180175A (fr) |
| IL (1) | IL258271B (fr) |
| MA (1) | MA43019A (fr) |
| MX (1) | MX391171B (fr) |
| MY (1) | MY193249A (fr) |
| PE (1) | PE20181089A1 (fr) |
| PH (1) | PH12018500707A1 (fr) |
| RU (1) | RU2761077C1 (fr) |
| TW (1) | TWI748964B (fr) |
| UA (1) | UA125685C2 (fr) |
| WO (1) | WO2017055328A1 (fr) |
| ZA (1) | ZA201801993B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3489256T3 (da) | 2014-11-14 | 2021-05-25 | Hoffmann La Roche | Antigenbindende molekyler omfattende en TNF-familieligandtrimer |
| EP3973980A1 (fr) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (fr) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| US20180064758A1 (en) * | 2016-09-05 | 2018-03-08 | Ucl Business Plc | Chimeric antigen receptor |
| IL267284B2 (en) | 2016-12-19 | 2023-03-01 | Hoffmann La Roche | Combination therapy with a targeted 4-bb1 agonist (cd137) |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| EP3565843A1 (fr) | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
| WO2018178055A1 (fr) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf |
| KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| MA49039A (fr) | 2017-04-04 | 2020-02-12 | Hoffmann La Roche | Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap |
| IL317928A (en) * | 2017-09-21 | 2025-02-01 | Wuxi Biologics Ireland Ltd | New anti-CD19 antibodies |
| CN111246884A (zh) | 2017-11-01 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 新颖的含有tnf家族配体三聚体的抗原结合分子 |
| KR102847676B1 (ko) * | 2017-12-15 | 2025-08-21 | 알레타 바이오쎄라퓨틱스, 인크. | Cd19 변이체 |
| CN108047332B (zh) * | 2018-01-15 | 2021-08-24 | 阿思科力(苏州)生物科技有限公司 | 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用 |
| CN112424228B (zh) | 2018-07-04 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 新型双特异性激动性4-1bb抗原结合分子 |
| PE20211863A1 (es) | 2018-10-01 | 2021-09-21 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap |
| WO2020127618A1 (fr) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs |
| US20220144917A1 (en) | 2019-03-01 | 2022-05-12 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of cd19 |
| WO2021067598A1 (fr) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Procédés pour une utilisation thérapeutique améliorée d'aav recombinant |
| JP7734132B2 (ja) * | 2019-12-11 | 2025-09-04 | カリナン セラピューティクス インコーポレイテッド | 抗血清アルブミン抗体 |
| WO2021119551A1 (fr) * | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anticorps anti-cd19 et protéines de liaison multi-spécifiques |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| TWI852680B (zh) * | 2020-06-19 | 2024-08-11 | 瑞士商赫孚孟拉羅股份公司 | 與 cd3 及 cd19 結合之抗體 |
| IL302569A (en) * | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60127143T2 (de) * | 2001-11-14 | 2007-11-15 | Affimed Therapeutics Ag | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
| SI1853718T1 (sl) * | 2005-02-15 | 2016-02-29 | Duke University | Protitelesa anti-CD19 in uporabe v onkologiji |
| CN101233156B (zh) * | 2005-06-20 | 2012-06-27 | 米德列斯公司 | Cd19抗体及其用途 |
| JP5825756B2 (ja) * | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) * | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| NZ598732A (en) * | 2009-10-27 | 2014-09-26 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
| WO2011147834A1 (fr) * | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Anticorps contre cd19 et utilisations associées |
| EP2409993A1 (fr) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré |
| BR112013024574B1 (pt) * | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| DK3489256T3 (da) * | 2014-11-14 | 2021-05-25 | Hoffmann La Roche | Antigenbindende molekyler omfattende en TNF-familieligandtrimer |
| EP3973980A1 (fr) * | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
-
2016
- 2016-09-28 KR KR1020187012274A patent/KR102761077B1/ko active Active
- 2016-09-28 UA UAA201804361A patent/UA125685C2/uk unknown
- 2016-09-28 MA MA043019A patent/MA43019A/fr unknown
- 2016-09-28 PE PE2018000446A patent/PE20181089A1/es unknown
- 2016-09-28 WO PCT/EP2016/073062 patent/WO2017055328A1/fr not_active Ceased
- 2016-09-28 CN CN201680057493.XA patent/CN108137698B/zh active Active
- 2016-09-28 CR CR20180175A patent/CR20180175A/es unknown
- 2016-09-28 MY MYPI2018701273A patent/MY193249A/en unknown
- 2016-09-28 JP JP2018516674A patent/JP6918789B2/ja active Active
- 2016-09-28 AU AU2016330807A patent/AU2016330807B2/en active Active
- 2016-09-28 MX MX2018003827A patent/MX391171B/es unknown
- 2016-09-28 RU RU2018115217A patent/RU2761077C1/ru active
- 2016-09-28 CA CA3000045A patent/CA3000045C/fr active Active
- 2016-09-28 EP EP16774655.1A patent/EP3356405A1/fr active Pending
- 2016-09-30 TW TW105131515A patent/TWI748964B/zh active
-
2018
- 2018-03-21 IL IL258271A patent/IL258271B/en unknown
- 2018-03-26 ZA ZA2018/01993A patent/ZA201801993B/en unknown
- 2018-03-28 PH PH12018500707A patent/PH12018500707A1/en unknown
- 2018-03-29 CL CL2018000829A patent/CL2018000829A1/es unknown
- 2018-03-30 US US15/941,519 patent/US20180230215A1/en not_active Abandoned
- 2018-04-26 CO CONC2018/0004532A patent/CO2018004532A2/es unknown
-
2019
- 2019-11-20 US US16/689,880 patent/US20200317774A1/en not_active Abandoned
-
2022
- 2022-11-03 US US18/052,526 patent/US20230312710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3000045C (fr) | 2024-01-02 |
| MX2018003827A (es) | 2018-06-22 |
| AU2016330807A1 (en) | 2018-04-12 |
| CN108137698A (zh) | 2018-06-08 |
| AU2016330807B2 (en) | 2023-08-10 |
| HK1256366A1 (zh) | 2019-09-20 |
| TWI748964B (zh) | 2021-12-11 |
| UA125685C2 (uk) | 2022-05-18 |
| ZA201801993B (en) | 2019-01-30 |
| CO2018004532A2 (es) | 2018-11-22 |
| US20180230215A1 (en) | 2018-08-16 |
| CN108137698B (zh) | 2022-04-19 |
| CL2018000829A1 (es) | 2019-05-03 |
| PE20181089A1 (es) | 2018-07-09 |
| CA3000045A1 (fr) | 2017-04-06 |
| PH12018500707A1 (en) | 2018-10-15 |
| IL258271B (en) | 2022-05-01 |
| RU2761077C1 (ru) | 2021-12-03 |
| TW201718654A (zh) | 2017-06-01 |
| BR112018006350A2 (en) | 2018-10-09 |
| MY193249A (en) | 2022-09-28 |
| WO2017055328A1 (fr) | 2017-04-06 |
| US20200317774A1 (en) | 2020-10-08 |
| IL258271A (en) | 2018-05-31 |
| EP3356405A1 (fr) | 2018-08-08 |
| JP2018535657A (ja) | 2018-12-06 |
| US20230312710A1 (en) | 2023-10-05 |
| JP6918789B2 (ja) | 2021-08-11 |
| MX391171B (es) | 2025-03-21 |
| CR20180175A (es) | 2018-05-03 |
| KR102761077B1 (ko) | 2025-02-04 |
| KR20180054863A (ko) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43019A (fr) | Anticorps anti-humain cd19 à affinité élevée | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (fr) | Anticorps anti-il1rap | |
| EP3387442A4 (fr) | Anticorps anti-cd73 humanisés | |
| HUE060019T2 (hu) | Anti-LAG3 antitestek | |
| EP3569709A4 (fr) | Anticorps anti-gpc3 | |
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| EP3334757A4 (fr) | Anticorps anti-tigit | |
| EP3297671A4 (fr) | Anticorps anti-ror1 | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EP3294335A4 (fr) | Anticorps anti-fcrn à maturation d'affinité humanisés | |
| DK3310809T3 (da) | Anti-cgrp-antistofformulering | |
| EP3691447A4 (fr) | Anticorps anti-transthyrétine | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| IL256097A (en) | Antibody epitope | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (fr) | Anticorps de liaison tau | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap |